H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE; INC.
发明人:
LANCASTER, Johnathan, M.,XIONG, Yin
申请号：
USUS2012/027737
公开号：
WO2012/122106A3
申请日:
2012.03.05
申请国别(地区):
WO
年份:
2012
代理人:
摘要：
Disclosed are compositions and methods for assessing the apoptosis and survival BAD phosphorylation pathway (BAD pathway) and/or (2) the cell cycle role of APC in cell cycle regulation pathway (APC pathway) and/or (3) the transcription CREB pathway (CREB pathway) and for using these pathways to assess, treat, monitor, prognose, diagnose, etc. subjects with cancer. Also disclosed are compositions and methods for identifying molecular pathways that are common to one or more chemotherapeutic agents for the treatment of an oncological disorder, for screening for compounds or agents that can be used to treat ovarian cancer, and for selecting for compounds or agents that can enhance the cytotoxic response of cisplatin, carboplatin, and/or paclitaxel against a cancer cell, such as an ovarian cancer cell or cell line. In some forms, the disclosed methods can comprise identifying compounds and/or agents that modulate the BAD pathway and/or the APC pathway and/or the CREB pathway. In some forms, the disclosed methods can comprise method for treating cancer using compounds and/or agents that modulate the BAD pathway and/or the APC pathway and/or the CREB pathway. Also disclosed are compositions, compounds, and agents identified using the disclosed methods.Linvention concerne des compositions et des procédés destinés à évaluer lapoptose et la voie de phosphorylation BAD de survie (voie BAD) et/ou (2) le rôle du cycle cellulaire de lAPC dans la voie de régulation du cycle cellulaire (voie APC) et/ou (3) la voie CREB de transcription (voie CREB) et à utiliser ces voies pour évaluer, traiter, réguler, pronostiquer, diagnostiquer, etc. des sujets atteints du cancer. Linvention concerne également des compositions et des procédés destinés à identifier des voies moléculaires communes à un ou plusieurs agents chimiothérapeutiques en vue du traitement dun trouble oncologique, afin de cribler des composés ou des agents pouvant être utilisés pour traiter un cancer des ovaires, et afin de
